Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Closed 11-26 16:00:00 EST

1.33

+0.00

0.00%

盘后1.33

+0.000.00%

18:42 EST

High1.35	Low1.32	Vol13.75K
Open1.33	D1 Closing1.33	Amplitude2.26%
Mkt Cap5.39M	Tradable Cap4.27M	Total Shares4.06M
T/O18.37K	T/O Rate0.43%	Tradable Shares3.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":1.33,"timestamp":1732654800000,"preClose":1.33,"halted":0,"volume":13749,"hourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.33,"latestTime":"18:42 EST","volume":35,"amount":47.25,"timestamp":1732664570471},"delay":0,"floatShares":3212760,"shares":4056335,"eps":-3.884092,"marketStatus":"Closed","change":0,"latestTime":"11-26 16:00:00 EST","open":1.33,"high":1.35,"low":1.32,"amount":18374.7919293,"amplitude":0.022556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.884092,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732698000000},"marketStatusCode":5,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":1.33,"postHourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.33,"latestTime":"18:42 EST","volume":35,"amount":47.25,"timestamp":1732664570471},"volumeRatio":0.347355},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2481605135","title":"Massachusetts psychedelics legalization initiative poised to fail","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605135","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481605135?lang=en_us&edition=fundamental","pubTime":"2024-11-06 14:55","pubTimestamp":1730876108,"startTime":"0","endTime":"0","summary":"Yarygin  A Massachusetts ballot question that would allow adults to grow, use, and possess many psychedelic substances appears poised for defeat. With 80% of precincts reporting, opponents of the measure are leading 56.7% to 43.3%. The substances that would be legalized under the proposal are psilocybin and psilocin, which are found in \"magic mushrooms,\" as well as dimethyltryptamine, mescaline, and ibogaine.  Oregon and Colorado already allow the use of some psychedelic substances. Psychedelic drug developers: Mind Medicine , Compass Pathways , Cybin , Atai Life Sciences , Enveric Bio , Revive Therapeutics , Bright Minds Biosciences , GH Research , Clearmind Medicine .","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4253295-massachusetts-psychedelics-legalization-initiative-poised-fail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["MNQmain","DRUG","BK4139","BK4007","BK4539","CYBN","GHRS","QID","QLD","BK4168","NQmain","MNMD","BK4547","CMPS","ENVB","DRUG.AU",".IXIC","PSQ","CMND","SQQQ","TQQQ","RVVTF","ATAI"],"gpt_icon":1},{"id":"2474178547","title":"Clearmind announces IRB approval for FDA first-in-human trial of CMND-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2474178547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474178547?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:16","pubTimestamp":1728562597,"startTime":"0","endTime":"0","summary":"Clearmind Medicine announced it has received Institutional Review Board, IRB, approval from one of its clinical sites in the U.S. for part A of its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2474712558","title":"Clearmind Medicine Announces Irb Approval for FDA First-in-Human Clinical Trial of Cmnd-100 at Second Clinical Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2474712558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474712558?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:07","pubTimestamp":1728562020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nTUA9PJJFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2474129187","title":"Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2474129187","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474129187?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:07","pubTimestamp":1728562020,"startTime":"0","endTime":"0","summary":"FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct.  10, 2024  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/10/2961273/0/en/Clearmind-Medicine-Announces-IRB-Approval-for-FDA-First-In-Human-Clinical-Trial-of-CMND-100-at-Second-Clinical-Site.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4125","BK4007","AUD","CMND"],"gpt_icon":0},{"id":"2468875238","title":"Clearmind Applies for Patent on Anti-Addiction Combination Therapy -- Shares Up After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2468875238","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468875238?lang=en_us&edition=fundamental","pubTime":"2024-09-17 05:45","pubTimestamp":1726523118,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said late Monday that it applied for an international patent application for its combination therapy of N-Acylethanolamines and Ibogaine, which is considered a potentially effective anti-addiction agent.The application follows developments in collaboration with SciSparc . The companies are researching new combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, Clearmind said.The company's shares were up more than 2% in after-hours activity, while SciSparc  jumped 16%.Price: 1.3600, Change: +0.03, Percent Change: +2.26","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CMND","SPRC","BK4139"],"gpt_icon":0},{"id":"2468220848","title":"Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2468220848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468220848?lang=en_us&edition=fundamental","pubTime":"2024-09-17 04:06","pubTimestamp":1726517160,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nTUA9NZNLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2466271186","title":"Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for Ptsd Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2466271186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466271186?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:20","pubTimestamp":1726143600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nTUA5YRFV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2466274442","title":"Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2466274442","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466274442?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:20","pubTimestamp":1726143600,"startTime":"0","endTime":"0","summary":"Innovative compounds designed to address critical unmet needs in PTSD treatment. Vancouver, Canada, Sept. 12, 2024  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty . This submission is part of the Company’s ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem , pursuant to the exclusive licensing agreement Clearmind holds with Yissum.The patent application covers innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel of the Hebrew University. These novel compounds are designed to treat post-traumatic stress disorder  and other mental health conditions.The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e2Iadkg5nMZi8NjoPUZ08w--~B/aD0zNzt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2ffd5670e8aaba248e02e858d0861289","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e2Iadkg5nMZi8NjoPUZ08w--~B/aD0zNzt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2ffd5670e8aaba248e02e858d0861289"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-yissum-file-international-122000327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2465001693","title":"Scisparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative Mdma-Based Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2465001693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465001693?lang=en_us&edition=fundamental","pubTime":"2024-09-06 19:55","pubTimestamp":1725623700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240906:nTUA2GRXV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"2465569696","title":"SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2465569696","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465569696?lang=en_us&edition=fundamental","pubTime":"2024-09-06 19:55","pubTimestamp":1725623700,"startTime":"0","endTime":"0","summary":"Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments. “The great importance of the cooperation with Clearmind lies in our unceasing attempts to offer effective and safe treatments and today's announcement is another demonstration of this methodology, as we believe that our combined approach may address some of the U.S. Food & Drug Administration’s concerns associated with MDMA safety,” said Oz Adler, Chief Executive Officer of SciSparc. “By integrating MDMA with N-Acylethanolamines like PEA, we aim to enhance both the safety and therapeutic potential of these treatments. This combination offers a promising path forward in the treatment of mental health disorders and addictions, providing an opportunity to overcome regulatory barriers and unlock the full potential of MDMA in clinical settings.”Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-deri","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-medicine-collaboration-leads-115500102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMND","BK4007","SPRC"],"gpt_icon":0},{"id":"2462467361","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2462467361","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462467361?lang=en_us&edition=fundamental","pubTime":"2024-08-25 21:54","pubTimestamp":1724594097,"startTime":"0","endTime":"0","summary":"The Cannabist Co. exits Florida market in $16.4 million sale.TerrAscend launched a $10 million share buyback program to enhance shareholder value.AFC Gamma provided over $18 million in credit to 3 cannabis operators.Cansortium reported its first profit of 2024, as the company plans expansion and RIV Capital acquisition.Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.In the first deal, an undisclosed MSO is purchasing the company’s 40,000-square-foot cultivation facility in Lakeland for $11.4 million. This payment will be made in cash, with $2 million already held in escrow.The Cannabist Co., formerly known as Columbia Care, operates 95 faci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-135457840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUD","BK4104","CMND","BK4161","MMTC","BK4007","REIT","MRC","BK4125","AFCG","BK4110"],"gpt_icon":0},{"id":"2461452753","title":"Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report","url":"https://stock-news.laohu8.com/highlight/detail?id=2461452753","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461452753?lang=en_us&edition=fundamental","pubTime":"2024-08-24 06:34","pubTimestamp":1724452452,"startTime":"0","endTime":"0","summary":"The U.S. FDA has been conducting interviews with several individuals familiar with clinical trials conducted by Lykos Therapeutics for its rejected MDMA-based PTSD therapy as it investigates potential improprieties.  The Wall Street Journal reported that at four individuals have been interviewed about the possibility some side effects -- including suicidal thoughts -- were not reported.  The newspaper noted that one person interviewed was asked about the techniques used in giving the therapy, called midomafetamine. Earlier in August, the FDA issued a Complete Response Letter to Lykos on the drug and asked the company to conduct an additional trial. Less than a week later, Lykos said it would lay off 75% of its workforce. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Cle","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4143520-trials-psychedlic-drug-candidate-ptsd-under-scrutiny-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNMD","QID","CMND","BK4547",".IXIC","MNQmain","QQQ","ATAI","PSQ","SQQQ","GHRS","BK4007","BK4139","CMPS","QLD","SEEL","CYBN","BK4168","NQmain","ENVB","ATNF","DRUG","TQQQ","SPRC","BK4539"],"gpt_icon":1},{"id":"2461580472","title":"Clearmind Receives Patent for Molecule That May Reduce Desire for Alcohol","url":"https://stock-news.laohu8.com/highlight/detail?id=2461580472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461580472?lang=en_us&edition=fundamental","pubTime":"2024-08-22 06:10","pubTimestamp":1724278200,"startTime":"0","endTime":"0","summary":"Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of a psychedelic molecule.The Vancouver clinical-stage psychedelic pharmaceutical biotech company said Wednesday its novel psychoactive molecule -- an amine aminoindane, including 5-methoxy-2-aminoindan, or MEAI -- reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience.The molecule is intended to treat alcohol use disorder and assist in weight loss. It may also be effective in treating binge drinking, the company said.The patent, granted by the U.S. Patent and Trademark Office, is the company's 29th across 19 patent families.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2461480113","title":"Clearmind Medicine Gets Patent Approval for Proprietary Binge Behavior Regulator Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2461480113","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461480113?lang=en_us&edition=fundamental","pubTime":"2024-08-22 05:38","pubTimestamp":1724276294,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2461011558","title":"Clearmind Medicine Gets Patent Approval for Proprietary Binge Behavior Regulator Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2461011558","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461011558?lang=en_us&edition=fundamental","pubTime":"2024-08-22 05:38","pubTimestamp":1724276294,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  shares were up 16% in recent after-hours activity Wednesday after the company said it received a new patent approval from the US Patent and Trademark Office for its proprietary binge behavior regulator program.The patent covers Clearmind's innovative psychedelic molecule 5-methoxy-2-aminoindan, among other things, according to the company.The latest patent expands the company's intellectual property portfolio to 29 patents across 19 patent families, Clearmind added.Price: 1.5200, Change: +0.22, Percent Change: +16.92","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2461803292","title":"Clearmind Medicine Inc - Granted U.S. Patent Approval for Binge Behavior Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2461803292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461803292?lang=en_us&edition=fundamental","pubTime":"2024-08-22 04:23","pubTimestamp":1724271814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240821:nFWN3K819N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2460221352","title":"Clearmind, Yissum Apply for International Patent for Psychedelics","url":"https://stock-news.laohu8.com/highlight/detail?id=2460221352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460221352?lang=en_us&edition=fundamental","pubTime":"2024-08-17 05:15","pubTimestamp":1723842900,"startTime":"0","endTime":"0","summary":"Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental disorders.The submission under the international Patent Cooperation Treaty is part of the company's collaboration with the Yissum Research Development Co. of Hebrew University of Jerusalem, with which Clearmind has a licensing agreement.Clearmind, of Vancouver, British Columbia, said the application refers to what it calls Generation 3.0 psychedelic compounds developed by the Israeli university's Dmitry Tsvelikhovsky.The biotechnology company also said the submission would allow it to proceed to the national phase and submit applications to regional offices for patent protection in major jurisdictions such as the U.S., Europe, China and India.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":1},{"id":"2460229406","title":"Clearmind Medicine and Yissum Expand Collaboration With International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2460229406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460229406?lang=en_us&edition=fundamental","pubTime":"2024-08-17 04:14","pubTimestamp":1723839240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240816:nTUA6VPQ9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2460822151","title":"Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2460822151","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460822151?lang=en_us&edition=fundamental","pubTime":"2024-08-17 04:14","pubTimestamp":1723839240,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Aug. 16, 2024  -- Clearmind Medicine Inc. ,  , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty  as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem  pursuant to the exclusive licensing agreement that the Company entered into with Yissum.This patent application refers to generation 3.0 of psychedelic compounds, methods of their preparation and uses thereof in the treatment of mental disorders and was developed by Prof. Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem.The PCT submission will allow the company to proceed to the national phase, which involves submitting applications to regional offices in various countries to seek patent protection in major jurisdictions like the US,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e2Iadkg5nMZi8NjoPUZ08w--~B/aD0zNzt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2ffd5670e8aaba248e02e858d0861289","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e2Iadkg5nMZi8NjoPUZ08w--~B/aD0zNzt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2ffd5670e8aaba248e02e858d0861289"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-yissum-expand-collaboration-201400780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2459401548","title":"Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2459401548","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459401548?lang=en_us&edition=fundamental","pubTime":"2024-08-16 03:02","pubTimestamp":1723748562,"startTime":"0","endTime":"0","summary":"Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board.  David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Clearmind Medicine .","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":[".IXIC","SQQQ","ATAI","ENVB","ATNF","GHRS","CYBN","BK4007","SPRC","NQmain","QID","BK4139","PSQ","CMND","BK4547","BK4539","MNQmain","CMPS","BK4168","DRUG","TQQQ","SEEL","MNMD","QLD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.089},{"period":"3month","weight":-0.0764},{"period":"6month","weight":0.177},{"period":"1year","weight":-0.6296},{"period":"ytd","weight":-0.5267}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction